Biotechnology

Cartesian Therapeutics

Cartesian Therapeutics released FY2026 Q1 earnings on April 30 (EST), actual revenue USD 78K (forecast USD 149.89K), actual EPS USD -1.459 (forecast USD -0.8842)

Cartesian Therapeutics released FY2025 Q4 earnings on March 9 (EST), actual revenue USD 947 K (forecast USD 100.22 K), actual EPS USD -3.5629 (forecast USD -0.8587)

Cartesian Therapeutics released FY2025 earnings on March 9 (EST), actual revenue USD 2.797 M (forecast USD 1.967 M), actual EPS USD -5.02 (forecast USD -2.35)

Wedbush's Martin Fan Maintains Buy Rating on Cartesian Therapeutics

Cartesian Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 452 K (forecast USD 177.56 K), actual EPS USD -1.3806 (forecast USD -0.845)

Cartesian Therapeutics released FY2025 9 Months earnings on November 6, 2025 (EST), actual revenue USD 1.85 M, actual EPS USD -1.5644

Needham analyst reiterates buy rating on Cartesian Therapeutics stock

Cartesian Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 298K (forecast USD 812.5K), actual EPS USD 0.5 (forecast USD -0.81)

Cartesian Therapeutics released FY2025 Semi-Annual earnings on August 7, 2025 (EST), actual revenue USD 1.398 M, actual EPS USD -0.1716

Cartesian Therapeutics Announces New Hiring Incentives

Cartesian Therapeutics Grants Stock Options to Three New Employees

Cartesian Therapeutics Launches Phase 3 AURORA Trial for Descartes-08

Cartesian Therapeutics Receives Analyst Ratings and Announces Quarterly Earnings

Cartesian Therapeutics released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 1.1 M (forecast USD 687.5 K), actual EPS USD -0.6837 (forecast USD -0.7057)

Cartesian Therapeutics Inc Reports Improved Quarterly Loss Per Share and Revenue Decline

Cartesian Therapeutics Inc Q1 2025 Earnings Report Shows 71 Cent Loss Per Share

Cartesian Therapeutics CTO to Depart and Serve as Advisor

Cartesian Therapeutics released FY2024 Annual Earnings on March 13 (EST), actual revenue USD 38.91 M (forecast USD 39.74 M), actual EPS USD -4.4813 (forecast USD -5.865)

Cartesian Therapeutics released FY2024 Q4 earnings on March 13 (EST), actual revenue USD -759 K (forecast USD 100 K), actual EPS USD -0.4033 (forecast USD -0.8257)

Cartesian Therapeutics Inc Expected to Release Earnings Report on March 5, 2024, Anticipating EPS Loss of $0.80 and Revenue Decline of 98.7%

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

RNAC

Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant of stock options to a new employee. The grant includes 6,100 shares with an exercise price of $5.86 per share, based on the June 8, 2026 closing price. Approved by the board under the 2018 Employment Inducement Incentive Award Plan, the options vest over time, becoming fully exercisable by June 8, 2030, and are valid for ten years.

Unusual Whales

Cartesian Therapeutics Announces New Employment Inducement Grant

CUPR

TXMD

During Friday's intraday session, several healthcare stocks experienced significant volatility. Cuprina Holdings surged 92.2% to $4.63, while Akanda rose 24.75%. Other gainers included Cartesian Therapeutics, Shattuck Labs, Aditxt, and TherapeuticsMD. Conversely, Gelteq plummeted 37.2% to $0.96, with BiomX, Propanc Biopharma, Aspire Biopharma, WORK Medical Tech, and AIM ImmunoTech also posting notable declines.

benzinga_article

AIM ImmunoTech

Therapeutics MD

Akanda

WORK Medical Tech

Aditxt

BiomX

Gelteq

Propanc Biopharma

Shattuck Labs

Aspire Biopharma

PROPANC BIOPHARMA INC

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

12 Health Care Stocks Moving In Friday's Intraday Session

ALHC

ELOX

RGNT

Top biotech gainers on Tuesday included Regentis (RGNT), up 88% on knee repair implant updates; Eloxx (ELOX), soaring 77% after Nasdaq uplisting and public offering; Alignment Healthcare (ALHC), rising 25% on executive RSU grants and revenue guidance; and Cartesian Therapeutics (RNAC), gaining 16% via a strategic CAR-T licensing deal with WestGene.

rttnews

Alignment Healthcare

Eloxx Pharmaceuticals

Regentis Biomaterials

Larimar Therapeutics

Top Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch

Cartesian Therapeutics (NASDAQ: RNAC) announced a strategic licensing agreement with WestGene Biopharma for an in vivo CAR-T platform, targeting autoimmune diseases like myasthenia gravis. A clinical trial is planned for late 2026. Following the news, RNAC stock surged approximately 17.75%. Despite strong analyst buy ratings and high price targets, technical indicators show weak momentum, with the stock trading below its 20-day moving average.

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

NUVL

ICCM

During Tuesday's intraday session, several healthcare stocks experienced significant volatility. ELOXX Pharma surged 2364.9% to $9.12, while Regentis Biomaterials rose 128.9%. Other gainers included Nuvalent, Rafael Holdings, Cartesian Therapeutics, and Alignment Healthcare. Conversely, Aditxt plummeted 43.3%, with iTonic Holdings, AIM ImmunoTech, Bio Green Med Solution, HCW Biologics, and Icecure Medical also posting notable declines.

Nuvalent

Rafael-B

Bio Green Med Solution

Icecure Medical

HCW Biologics

iTonic

12 Health Care Stocks Moving In Tuesday's Intraday Session

Cartesian Therapeutics shares are trading higher after announcing a strategic licensing agreement with WestGene to advance the development of in vivo chimeric antigen receptor T-cell therapies in autoimmune diseases.

BJDX

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Regentis Biomaterials surged 128.9% to $2.93, while Aditxt and Nuvalent rose over 40%. QTREX Quantum, Icecure Medical, and Cartesian Therapeutics also gained ground. Conversely, iTonic Holdings dropped 34.8%, with MetaVia, Inotiv, Redhill Biopharma, Bio Green Med Solution, and Bluejay Diagnostics declining between 11% and 22%.

Cartesian Therapeutics(RNAC.US)